<!DOCTYPE html><html prefix="og: http://ogp.me/ns#" lang="zh">
<!-- Mirrored from cn.nytimes.com/business/20201207/china-vaccine-astrazeneca/zh-hant/dual/ by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 28 Jan 2022 14:11:36 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head><meta charset="UTF-8"><!-- Browser render  --><meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1"><meta name="renderer" content="webkit"><!-- End Browser render --><meta name="keywords" content=""><meta name="description" content="康泰將成為阿斯利康新冠疫苗在中國大陸的獨家生產商，也在測試自己的疫苗。但中國疫苗行業飽受腐敗和爭議困擾，康泰及其老闆杜偉民更是身處多起醜聞中心。"><meta id="uuid" name="uuid" content="933bd98d0b2d75f1d07176d403950d7b"><meta id="headline" name="headline" content="中國「疫苗之王」：成功與財富幕布下的醜聞與爭議 - 紐約時報中文網"><meta id="byline" name="byline" content="黃瑞黎,赫海威"><meta id="date" name="date" content="2020-12-08T09:53:20.000Z"><link rel="alternate" href="../../index.html" hreflang="zh-Hans"><link rel="alternate" href="../index.html" hreflang="zh-Hant"><link rel="alternate" href="https://www.nytimes.com/2020/12/07/business/china-vaccine-astrazeneca.html" hreflang="en-us"><link rel="canonical" href="../index.html"><link rel="alternate" type="application/rss+xml" href="https://cn.nytimes.com/rss/zh-hant/"><meta name="apple-itunes-app" content="app-id=807498298, app-argument=nytimescn://article:933bd98d0b2d75f1d07176d403950d7b"><meta name="lang" property="lang" content="zh-cmn-hant"><!-- Apple IOS safari private meta --><link rel="apple-touch-icon-precomposed" sizes="144×144" href="../../../../../../static01.nyt.com/images/icons/ios-ipad-144x144.png"><link rel="apple-touch-icon-precomposed" sizes="114×114" href="../../../../../../static01.nyt.com/images/icons/ios-iphone-114x144.png"><link rel="apple-touch-icon-precomposed" href="../../../../../../static01.nyt.com/images/icons/ios-default-homescreen-57x57.png"><meta name="apple-mobile-web-app-title" content="中國「疫苗之王」：成功與財富幕布下的醜聞與爭議 - 紐約時報中文網"><meta name="apple-mobile-web-app-capable" content="yes"><!-- End Apple IOS safari private meta --><!-- Viewport and mobile --><meta name="viewport" content="width=device-width,initial-scale=1,user-scalable=no,maximum-scale=1,minimum-scale=1,minimal-ui"><!-- End viewport and mobile --><meta http-equiv="Cache-Control" content="no-siteapp"><meta name="format-detection" content="telephone=no"><meta name="HandheldFriendly" content="true"><meta name="MobileOptimized" content="320"><meta name="x5-orientation" content="portrait"><meta name="full-screen" content="yes"><meta name="x5-fullscreen" content="true"><meta name="browsermode" content="application"><meta name="x5-page-mode" content="app"><meta name="msapplication-tap-highlight" content="no"><meta property="og:title" content="中國「疫苗之王」：成功與財富幕布下的醜聞與爭議"><meta property="og:type" content="article"><meta property="og:url" content="../index.html"><meta property="og:description" content="康泰將成為阿斯利康新冠疫苗在中國大陸的獨家生產商，也在測試自己的疫苗。但中國疫苗行業飽受腐敗和爭議困擾，康泰及其老闆杜偉民更是身處多起醜聞中心。"><meta property="og:site_name" content="紐約時報中文網"><meta property="article:publisher" content="https://www.facebook.com/nytimeschinese"><meta property="article:published_time" content="2020-12-08T09:53:20.000Z"><meta property="fb:pages" content="1504603339831430"><meta property="fb:app_id" content="853699254762608"><meta property="og:image" content="../../../../../../static01.nyt.com/images/2020/12/04/business/00China-vaccine-illo/00China-vaccine-illo-videoLarge.html"><meta property="twitter:card" content="summary_large_image"><meta property="twitter:url" content="../index.html"><meta property="twitter:title" content="中國「疫苗之王」：成功與財富幕布下的醜聞與爭議"><meta property="twitter:description" content="康泰將成為阿斯利康新冠疫苗在中國大陸的獨家生產商，也在測試自己的疫苗。但中國疫苗行業飽受腐敗和爭議困擾，康泰及其老闆杜偉民更是身處多起醜聞中心。"><meta property="twitter:domain" content="cn.nytimes.com"><meta property="twitter:site" content="@nytchinese"><meta property="twitter:creator" content="@nytchinese"><meta property="twitter:image:src" content="../../../../../../static01.nyt.com/images/2020/12/04/business/00China-vaccine-illo/00China-vaccine-illo-videoLarge.html"><meta name="PT" content="article"><meta name="PST" content="News"><meta name="CG" content="business"><meta name="SCG" content=""><meta name="sourceApp" content="nyt-china-web"><meta name="ptime" content="20201207072043"><meta name="utime" content="20201208095320"><meta name="pdate" content="20201208"><meta name="dat" content="Dec. 07, 2020"><meta name="hdl" content="中國「疫苗之王」：成功與財富幕布下的醜聞與爭議"><meta name="byl" content="黃瑞黎,赫海威"><meta name="lp" content="康泰將成為阿斯利康新冠疫苗在中國大陸的獨家生產商，也在測試自己的疫苗。但中國疫苗行業飽受腐敗和爭議困擾，康泰及其老闆杜偉民更是身處多起醜聞中心。"><link rel="shortcut icon" href="https://static01.nyt.com/favicon.ico"><link rel="stylesheet" href="../../../../../../d1f1eryiqyjs0r.cloudfront.net/style/css/nytcn_core/style-flex.min619b.css?v=f1810d8"><link rel="stylesheet" href="../../../../../../d1f1eryiqyjs0r.cloudfront.net/style/css/web/style.min619b.css?v=f1810d8"><link rel="stylesheet" href="../../../../../../d1f1eryiqyjs0r.cloudfront.net/style/css/nytcn_core/article.min619b.css?v=f1810d8"><link rel="stylesheet" href="../../../../../../d1f1eryiqyjs0r.cloudfront.net/style/css/slideshow/slideshow.min619b.css?v=f1810d8"><link rel="stylesheet" href="../../../../../../d1f1eryiqyjs0r.cloudfront.net/style/css/cookie-banner/style.min619b.css?v=f1810d8"><title>中國「疫苗之王」：成功與財富幕布下的醜聞與爭議 - 紐約時報中文網</title></head><script>var js_static_path = "https://d1f1eryiqyjs0r.cloudfront.net/js";
 var imgs_static_path = "https://d1f1eryiqyjs0r.cloudfront.net/style/imgs";
 var style_static_path = "https://d1f1eryiqyjs0r.cloudfront.net/style";
 var site = 1;
 var sectionName = "business";
 var adTyp = "art";
 var cookieString = {
     "title": "您的追蹤器設置",
     "headline": "我們使用 cookie 做什麼？",
     "summary": '<p>我們利用cookies和類似的技術識別您的重複訪問和偏好。我們還使用它們來衡量廣告系列的效果，定位廣告並分析和網站流量。更多關於cookies的資訊（包括如何停用），<a href="https://www.nytimes.com/zh-hant/privacy/cookie-policy" rel="noreferrer noopener" target="_blank" data-testid="GDPR-policy">請查看我們的「Cookie政策」</a>。</span><span>自2020年7月20日起，我們將根據您在我們服務中所訪問的內容類型向您顯示我們認為與您的興趣相關的廣告。您可以<a href="https://www.nytimes.com/zh-hant/privacy/cookie-policy#how-do-i-manage-trackers" rel="noreferrer noopener" target="_blank" data-testid="GDPR-objection">提出反對</a>。希望了解更多信息，請參見我們的<a href="https://nytimes.com/zh-hant/privacy/privacy-policy#we-allow-for-personalized-advertising-on-times-services" rel="noreferrer noopener" target="_blank" data-testid="GDPR-privacy">隱私政策</a>。</p><p>透過在此處點擊「我接受」或者「X」， 您將被視為同意使用cookies。您隨時可以通過我們的Cookie政策來更改您的跟踪器偏好。</p>',
     "button": "接受",
     "trackerButton": "您的追蹤器設置",
     "rejectButton": "拒絕所有",
     "lang": 'zh-hant',
     "trackerLink": "https://www.nytimes.com/zh-hant/privacy/cookie-policy",
 };
 var purrString = {
     "button": "請勿出售我的個人資訊",
     "snackbar": "你的設定已經保存在此瀏覽器和設備上。如果你清除了 cookie，這些設定也會被清除。",
     "snackbarError": "Something went wrong",
     "optedOutText": "我们不再出售您的個人資訊",
     "CFALinkText": "California Notices",
     "purrPopupTitle": "Your request to not sell your data will be stored for this browser and device",
     "purrPopupSummary": "If you clear your cookies, your preference will be forgotten. As a California resident, you have additional rights under the California Consumer Privacy Act of 2018. While The New York Times Company does not “sell” personal information of its readers as the term “sell” is traditionally understood, “sell” under the CCPA is broadly defined. To learn more, review the text below.",
     "purrPopupButton": "DISMISS",
     "purrPopupScrollContent": 'ssa sed. Nec sagittis aliquam malesuada bibendum arcu. Nunc sed blandit libero volutpat sed cras ornare arcu. Metus vulputate eu scelerisque felis imperdiet proin. Elit eget gravida cum sociis natoque penatibus. Sodales ut eu sem integer. Vitae auctor eu augue ut lectus arcu bibendum at. Vulputate ut pharetra sit amet aliquam id diam. Eu tincidunt tortor aliquam nulla facilisi cras fermentum odio eu. Imperdiet dui accumsan sit amet nulla facilisi morbi. Laoreet non curabitur gravida arcu ac tortor dignissim. Magna fringilla urna porttitor rhoncus dolor purus. In nulla posuere sollicitudin aliquam. At elementum eu facilisis sed odio. Diam in arcu cursus euismod quis viverra. Viverra suspendisse potenti nullam ac tortor vitae purus. Felis donec et odio pellentesque diam volutpat. Lacus sed turpis tincidunt id aliquet risus feugiat in.Aliquam ut porttitor leo a diam sollicitudin tempor',
     "lang": 'zh-hant'
 };
 cbSectionName = "business";
 cbByline = "黃瑞黎,赫海威";</script><!-- Google Tag Manager --><script>(function(w,d,s,l,i){
     w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});
     var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';
     j.async=true;j.src='../../../../../../www.googletagmanager.com/gtm5445.html?id='+i+dl;
     f.parentNode.insertBefore(j,f);
 })(window,document,'script','dataLayer','GTM-KTDZV8V');</script><!-- End Google Tag Manager --><!-- chartbeat --><script type="text/javascript">var _sf_startpt=(new Date()).getTime()</script><!-- /chartbeat --><body class="news"><main class="container-fluid main clearfix"><header class="row title-bar"><div class="nav-button default" id="menuBtn"><i class="icon-bars"></i></div><h1 class="logo"><a href="/"><svg role="img" aria-label="" width="90%" height="90%"><image width="100%" height="100%" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="/d1f1eryiqyjs0r.cloudfront.net/style/imgs/mweb/nytimes-zh-hant.svg" src="../../../../../../d1f1eryiqyjs0r.cloudfront.net/style/imgs/mweb/nytimes-zh-hant%402x.png" alt="" border="0"></image></svg></a></h1><div class="nav-button default" id="gearBtn"><i class="icon-gear"></i></div><div class="popup gear-popup"><div class="tips-container"><div class="tips-border"></div><div class="tips-inner"></div></div><div class="popup-container"><div class="popup-body"><div class="setting-title">簡繁中文</div><div class="setting-option"><a href="../../index024e.html?changeLang=zh-hans">簡體 </a><a href="../../index27d8.html?changeLang=zh-hant" class="active">繁體</a></div><div class="setting-title">紐約時報 出版語言</div><ul class="menu-list"><li><a href="https://www.nytimes.com/">ENGLISH (英語)</a></li><li><a href="https://www.nytimes.com/es/">ESPAÑOL (西班牙語)</a></li></ul><div class="setting-title">字體大小</div><div class="setting-option"><div class="form-check form-check-inline"><label class="form-check-label"><input class="form-check-input font-size" type="radio" name="changeFontSizeRadio" value="small"> 小</label></div><div class="form-check form-check-inline"><label class="form-check-label"><input class="form-check-input font-size" type="radio" name="changeFontSizeRadio" value="normal" checked="checked"> 中</label></div><div class="form-check form-check-inline"><label class="form-check-label"><input class="form-check-input font-size" type="radio" name="changeFontSizeRadio" value="large"> 大</label></div><div class="form-check form-check-inline"><label class="form-check-label"><input class="form-check-input font-size" type="radio" name="changeFontSizeRadio" value="xlarge"> 超大</label></div></div></div></div></div></header><div class="top_banner_ad" id="topad" data-target="{&quot;pos&quot;:&quot;top&quot;,&quot;adv&quot;:&quot;&quot;}"></div><div class="article-area"><div class="setting-bar row"><div class="col-4 section-title"><h3>商業與經濟</h3></div><div class="col-8 setting-btns"><div class="row"><div class="col-6"><ul class="dual-btn"><li><a href="../../index.html"><span class="setting-btn-text">中文</span> <span class="setting-btn-text-mobile">中</span></a></li><li><a href="javascript:;" class="active"><span class="setting-btn-text">中英雙語</span> <span class="setting-btn-text-mobile">雙語</span></a></li><li><a href="https://www.nytimes.com/2020/12/07/business/china-vaccine-astrazeneca.html" target="_blank"><span class="setting-btn-text">英文 <i class="icon-share-square"></i> </span><span class="setting-btn-text-mobile">英</span></a></li></ul></div><div class="col-6 share-tools-top-container"><ul class="share-tools mobile-article"><li><a href="http://v.t.sina.com.cn/share/share.php?&amp;title=%E4%B8%AD%E5%9C%8B%E3%80%8C%E7%96%AB%E8%8B%97%E4%B9%8B%E7%8E%8B%E3%80%8D%EF%BC%9A%E6%88%90%E5%8A%9F%E8%88%87%E8%B2%A1%E5%AF%8C%E5%B9%95%E5%B8%83%E4%B8%8B%E7%9A%84%E9%86%9C%E8%81%9E%E8%88%87%E7%88%AD%E8%AD%B0&amp;url=https://cn.nytimes.com/business/20201207/china-vaccine-astrazeneca/zh-hant/" target="_blank"><i class="icon-weibo"></i></a></li><!-- <li> --><!-- <a href="javascript:void(0);" class="JS_shareForQrcode" data-url="https://cn.nytimes.com/business/20201207/china-vaccine-astrazeneca/zh-hant/" data-headline="%E4%B8%AD%E5%9C%8B%E3%80%8C%E7%96%AB%E8%8B%97%E4%B9%8B%E7%8E%8B%E3%80%8D%EF%BC%9A%E6%88%90%E5%8A%9F%E8%88%87%E8%B2%A1%E5%AF%8C%E5%B9%95%E5%B8%83%E4%B8%8B%E7%9A%84%E9%86%9C%E8%81%9E%E8%88%87%E7%88%AD%E8%AD%B0"> --><!-- <i class="icon-wechat"></i> --><!-- </a> --><!-- </li> --><li><a href="https://www.facebook.com/sharer/sharer.php?u=https://cn.nytimes.com/business/20201207/china-vaccine-astrazeneca/zh-hant/" trage="_blank"><i class="icon-facebook"></i></a></li><li><a href="https://plus.google.com/share?url=https://cn.nytimes.com/business/20201207/china-vaccine-astrazeneca/zh-hant/" target="_blank"><i class="icon-google"></i></a></li><li><a href="https://twitter.com/share?text=%E4%B8%AD%E5%9C%8B%E3%80%8C%E7%96%AB%E8%8B%97%E4%B9%8B%E7%8E%8B%E3%80%8D%EF%BC%9A%E6%88%90%E5%8A%9F%E8%88%87%E8%B2%A1%E5%AF%8C%E5%B9%95%E5%B8%83%E4%B8%8B%E7%9A%84%E9%86%9C%E8%81%9E%E8%88%87%E7%88%AD%E8%AD%B0&amp;url=https://cn.nytimes.com/business/20201207/china-vaccine-astrazeneca/zh-hant/" target="_blank"><i class="icon-twitter"></i></a></li><li><div class="line-it-button" data-lang="zh_Hant" data-type="share-g" data-url="https://cn.nytimes.com/business/20201207/china-vaccine-astrazeneca/zh-hant/" style="display: none;"></div><script src="../../../../../../d.line-scdn.net/r/web/social-plugin/js/thirdparty/loader.min.js" async="async" defer="defer"></script></li><!-- <li> --><!-- <a href="javascript:void(0);" class="JS_shareForQrcode" data-url="https://cn.nytimes.com/business/20201207/china-vaccine-astrazeneca/zh-hant/" data-headline="%E4%B8%AD%E5%9C%8B%E3%80%8C%E7%96%AB%E8%8B%97%E4%B9%8B%E7%8E%8B%E3%80%8D%EF%BC%9A%E6%88%90%E5%8A%9F%E8%88%87%E8%B2%A1%E5%AF%8C%E5%B9%95%E5%B8%83%E4%B8%8B%E7%9A%84%E9%86%9C%E8%81%9E%E8%88%87%E7%88%AD%E8%AD%B0"> --><!-- <i class="icon-qrcode"></i> --><!-- </a> --><!-- </li> --></ul><div class="share-btn"><i class="icon-forward"></i></div></div></div></div></div><article class="article-content article-dual font-normal"><div class="article-header"><header><small></small><h1>中國「疫苗之王」：成功與財富幕布下的醜聞與爭議</h1><h1 class="en-title">Scandal Dogs China’s ‘King of Vaccines,’ Partner to AstraZeneca</h1></header><div class="byline-row"><div class="byline-box"><div class="byline"><address>黃瑞黎, 赫海威</address><time pudate="2020-12-08 09:53:20" datetime="2020-12-08 09:53:20">2020年12月7日</time></div><div class="share-btn"><i class="icon-forward"></i></div></div></div></div><figure class="article-span-photo small-span-photo"><img src="../../../../../../static01.nyt.com/images/2020/12/04/business/00China-vaccine-illo/00China-vaccine-illo-jumbo.html" width="755" height="1024" alt=""><figcaption><span></span> <cite>Nicolas Ortega</cite></figcaption></figure><div class="row"><section class="article-body"><div class="article-partial"><div class="article-body-item col-lg-5"><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">As a government regulator sidled into a car, the Chinese pharmaceutical executive handed over a paper bag stuffed with $44,000 in cash.</div></div><div class="col-lg-6"><div class="article-paragraph">當一位政府監管官員側身上車的時候，一家中國製藥公司的高管將一個裝有30萬元現金的紙袋遞了進去。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">The executive, Du Weimin, was eager to get his company’s vaccines approved, and he needed help. The official took the money and vowed to try his best, according to court documents.</div></div><div class="col-lg-6"><div class="article-paragraph">這位高管就是杜偉民，他急於讓自己公司的疫苗獲得批准，因此需要幫助。根據法庭文件，該官員拿走了這筆錢，並保證會盡力而為。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">Several months later, Mr. Du got the greenlight to begin clinical trials for two vaccines. They were ultimately approved, generating tens of millions of dollars in revenue.</div></div><div class="col-lg-6"><div class="article-paragraph">幾個月後，杜偉民獲准開始兩種疫苗的臨床試驗。這兩種疫苗最終獲得批准，帶來了數千萬美元的收入。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">The government official was jailed in 2016 for taking bribes from Mr. Du and several other vaccine makers.<strong> </strong>Mr. Du was never charged.</div></div><div class="col-lg-6"><div class="article-paragraph">2016年，該政府官員因收受杜偉民和其他幾家疫苗生產商的賄賂而入獄。杜偉民從未被起訴。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">Instead, he built an empire. His company, Shenzhen Kangtai Biological Products, is one of China’s largest vaccine makers. And Mr. Du, dubbed the “<a rel="noopener noreferrer" target="_blank" href="http://news.163.com/18/0722/17/DNB9RKDH0001899N.html">king of vaccines</a>,” is one of the richest men in China.</div></div><div class="col-lg-6"><div class="article-paragraph">相反，他建立了一個帝國。他的深圳康泰生物製品有限公司是中國最大的疫苗生產商之一。被稱為「<a rel="noopener noreferrer" target="_blank" href="http://news.163.com/18/0722/17/DNB9RKDH0001899N.html">疫苗之王</a>」的杜偉民則是中國最富有的人之一。</div></div></div><figure class="article-inline-photo"><div class="img-box"><img src="../../../../../../static01.nyt.com/images/2020/12/04/business/00china-vaccine6/merlin_180810627_60628b67-b8f5-4931-a236-77365f077d09-master1050.html" alt="深圳康泰生物製品公司董事長杜偉民被稱為 &quot;疫苗之王&quot;，是中國最富有的人之一。" data-src="https://static01.nyt.com/images/2020/12/04/business/00china-vaccine6/merlin_180810627_60628b67-b8f5-4931-a236-77365f077d09-master1050.jpg"></div><figcaption><span>深圳康泰生物製品公司董事長杜偉民被稱為 "疫苗之王"，是中國最富有的人之一。</span> <cite>Yu Ga/Visual China</cite></figcaption></figure><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">Capitalizing on that success, Mr. Du and his company are now at the forefront of the <a href="https://www.nytimes.com/2020/03/19/us/politics/coronavirus-vaccine-competition.html">global race</a> to produce a <a href="https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html">coronavirus vaccine</a>, a <a href="https://www.nytimes.com/2020/09/11/business/china-vaccine-diplomacy.html">national priority</a> for China’s ruling Communist Party. Kangtai will be the exclusive manufacturer in mainland China for the vaccine made by the British-Swedish pharmaceutical giant <a href="https://www.nytimes.com/2020/11/24/health/astrazeneca-covid-vaccine.html">AstraZeneca</a>, and the companies could work together on deals for other countries. The Chinese company is also in early trials for its own candidate.</div></div><div class="col-lg-6"><div class="article-paragraph">依靠這樣的成功，杜偉民和他的公司如今在<a href="https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html">新冠病毒疫苗</a>生產的<a href="https://www.nytimes.com/2020/03/19/us/politics/coronavirus-vaccine-competition.html">全球競賽</a>中處於領先地位，這對中國共產黨來說是<a href="../../../../20200911/china-vaccine-diplomacy/dual/index.html">國家的首要任務</a>。康泰將成為英國-瑞典合資製藥巨頭<a href="https://www.nytimes.com/2020/11/24/health/astrazeneca-covid-vaccine.html">阿斯利康(AstraZeneca)</a>的疫苗在中國大陸的獨家生產商，這兩家公司還可以在其他國家的疫苗交易上進行合作。這家中國公司也在為其候選疫苗進行早期試驗。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">Mr. Du’s success, against the backdrop of scandal, is not an outlier in China. It is the norm.</div></div><div class="col-lg-6"><div class="article-paragraph">杜偉民醜聞之下的成功在中國並非例外。而是常態。</div></div></div></div><div class="article-body-aside col-lg-3"><div id="subscribe_cont" style="margin: 0 auto;" class="container"></div></div></div><div class="big_ad" id="medium-rectangle-ad-0" data-target="{&quot;pos&quot;:&quot;mid1&quot;,&quot;adv&quot;:&quot;&quot;}"><small>廣告</small></div><div class="article-partial"><div class="article-body-item col-lg-5"><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">As the Chinese government has pushed to develop vaccine companies of global renown, the state has fostered and protected an industry plagued by <a href="https://www.nytimes.com/2020/05/04/business/coronavirus-china-vaccine.html">corruption</a> and <a href="https://www.nytimes.com/2019/01/14/business/china-vaccine-scandal-protests.html">controversy</a>.</div></div><div class="col-lg-6"><div class="article-paragraph">在中國政府推動建設享譽全球的疫苗公司之際，國家扶持並保護了這個飽受<a href="../../../../20200506/coronavirus-china-vaccine/index.html">腐敗</a>和<a href="../../../../20190115/china-vaccine-scandal-protests/index.html">爭議</a>困擾的行業。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">Drug companies, eager to get their products into the hands of consumers, have used <a href="https://www.nytimes.com/2018/09/30/business/china-health-care-doctors.html">financial incentives</a> to sway poorly compensated government workers for regulatory approvals.<strong> </strong>Hundreds of Chinese officials have been accused in recent years of taking bribes in cases involving vaccine companies, according to a review of court records. The companies and executives implicated rarely face punishment.</div></div><div class="col-lg-6"><div class="article-paragraph">急於將產品送到消費者手中的製藥公司利用<a href="../../../../20181018/china-health-care-doctors/index.html">財務激勵手段</a>打動薪水微薄的政府員工，以獲得監管部門的批准。查閱法庭記錄顯示，近年來，有數百名官員被控在涉及疫苗企業的案件中收受賄賂。牽涉其中的企業和高管很少受到懲罰。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">Oversight has been weak, contributing to a spate of scandals over substandard vaccines. While the government after each incident has vowed to do more to <a href="https://www.nytimes.com/2018/07/23/world/asia/china-vaccines-scandal-investigation.html">clean up the industry</a>,<strong> </strong>regulators have rarely provided much information about what went wrong. Companies have often emerged unscathed after making an apology or <a href="https://www.nytimes.com/2018/10/17/business/china-vaccine-fine.html">paying a fine</a>, and in nearly all instances, they have been allowed to continue operating.</div></div><div class="col-lg-6"><div class="article-paragraph">監管的薄弱導致了大量不合格疫苗醜聞的發生。雖然政府在每次事故後都承諾要採取更多措施<a href="#https://cn.nytimes.com/china/20180724/china-vaccines-scandal-investigation/">整頓行業</a>，但監管機構很少提供關於問題出在哪裡的信息。企業往往在道歉或<a href="#https://cn.nytimes.com/china/20181018/china-vaccine-fine/">支付罰款</a>之後毫髮無損，而且幾乎沒有例外的是，它們都被允許繼續經營下去。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">Dr. Ray Yip, a former head of the Bill and Melinda Gates Foundation in China, said he considers Kangtai to be among the top tiers of the country’s vaccine companies, adding that he “has no problem” with the manufacturing and technology standards of most players.</div></div><div class="col-lg-6"><div class="article-paragraph">比爾和梅琳達·蓋茲基金會(Bill and Melinda Gates Foundation)前中國負責人葉雷(Ray Yip)表示，他認為康泰是中國最頂尖的疫苗企業之一，並補充說他對大多數疫苗企業的生產和技術標準「沒有意見」。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">“The problem for many of them is their business practice,” said Dr. Yip, who also led the China office of the U.S. Centers for Disease Control and Prevention. “They all want to sell to the local governments, so they have to do kickbacks, they have to bribe. That’s the Achilles’ heel of China’s vaccine business.”</div></div><div class="col-lg-6"><div class="article-paragraph">「這些企業中許多的問題出在他們的商業行為上，」同時也是美國疾病控制與預防中心(U.S. Centers for Disease Control and Prevention)中國辦事處負責人的葉雷說。「他們都想把產品賣給地方政府，所以必須給回扣，必須行賄。這是中國疫苗生意的致命弱點。」</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">Kangtai did not respond to multiple requests for comment.</div></div><div class="col-lg-6"><div class="article-paragraph">康泰沒有回覆記者的多次置評請求。</div></div></div></div><div class="article-body-aside col-lg-3"></div></div><div class="big_ad" id="medium-rectangle-ad-1" data-target="{&quot;pos&quot;:&quot;mid2&quot;,&quot;adv&quot;:&quot;&quot;}"><small>廣告</small></div><div class="article-partial"><div class="article-body-item col-lg-5"><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">In a statement, AstraZeneca said it “conducts appropriate and thorough due diligence prior to entering an agreement with any entity.”</div></div><div class="col-lg-6"><div class="article-paragraph">阿斯利康在一份聲明中表示，該公司「在與任何實體達成協議之前，都進行了妥當和徹底的盡職調查」。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">“Safety, efficacy and quality of the vaccine is of utmost importance, and AstraZeneca has partnered with capable, established organizations to help ensure broad and equitable global access, at no profit during the pandemic,” the company said.</div></div><div class="col-lg-6"><div class="article-paragraph">「疫苗的安全性、有效性和質量至關重要，阿斯利康已與出色的知名機構合作，在疫情期間不盈利的情況下，幫助確保疫苗廣泛而公平的全球可及性，」該公司表示。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">The lack of transparency, compounded by dubious business practices, has rattled public confidence in Chinese-made vaccines, even though they have been proved safe. Many well-off parents shun them, preferring their Western counterparts.</div></div><div class="col-lg-6"><div class="article-paragraph">缺乏透明度，再加上可疑的商業行為，動搖了公眾對中國產疫苗的信心，哪怕它們已被證明是安全的。許多富裕的家長避之不及，更願意選擇西方的疫苗。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">In 2013, <a href="https://www.nytimes.com/2013/12/26/world/asia/china-investigates-vaccine-maker-after-infant-deaths.html">17 infants died</a> after injections with Kangtai’s hepatitis B vaccine. Regulators cleared Kangtai of wrongdoing, and the vaccine continues to be used safely. But the government didn’t provide substantial details about its investigation into the deaths or Kangtai’s safety practices; the company had negative articles retracted.</div></div><div class="col-lg-6"><div class="article-paragraph">2013年，<a href="https://www.nytimes.com/2013/12/26/world/asia/china-investigates-vaccine-maker-after-infant-deaths.html">17名嬰兒</a>在注射了康泰的乙肝疫苗後死亡。監管機構排除了康泰的不當行為，該疫苗仍在安全使用。但政府沒有提供有關死亡事故的調查或康泰安全措施的實質性細節；該公司已經撤下了負面報導。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">Distraught parents around the world <a href="https://www.nytimes.com/2019/06/18/health/vaccine-injury-claims.html">blame vaccine makers</a> for their children’s illnesses or their untimely deaths, often without scientific evidence. But in China, the government muzzles many families, further feeding suspicions about Chinese-made vaccines.</div></div><div class="col-lg-6"><div class="article-paragraph">全世界都有憂心忡忡的父母將他們孩子的疾病或夭折<a href="https://www.nytimes.com/2019/06/18/health/vaccine-injury-claims.html">歸咎於疫苗生產商</a>，這些指控往往缺乏科學證據。但在中國，政府迫使許多家庭緘口不言，進一步加深了人們對中國產疫苗的懷疑。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">Activists who have called for greater scrutiny of pharmaceutical companies, including Kangtai, have been harassed, intimidated and detained. Worried about the threat to social stability, Chinese officials have tried to stop them from organizing, by shuttering social media groups and monitoring their communications.</div></div><div class="col-lg-6"><div class="article-paragraph">呼籲對包括康泰在內的製藥公司進行更嚴格審查的活動人士遭到了騷擾、恐嚇和拘留。出於對社會穩定的擔憂，中國官員們試圖靠封禁社群媒體群組和監控通訊來阻止他們組織活動。</div></div></div></div><div class="article-body-aside col-lg-3"></div></div><div class="big_ad" id="medium-rectangle-ad-2" data-target="{&quot;pos&quot;:&quot;mid3&quot;,&quot;adv&quot;:&quot;&quot;}"><small>廣告</small></div><div class="article-partial"><div class="article-body-item col-lg-5"><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">Yanzhong Huang, a senior fellow for global health at the Council on Foreign Relations, said the 2013 scandal “raises legitimate concerns” about Kangtai.</div></div><div class="col-lg-6"><div class="article-paragraph">美國對外關係委員會(Council on Foreign Relations)負責全球衛生事務的高級研究員黃嚴忠表示，2013年的醜聞「引發了人們」對康泰的「合理擔憂」。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">“The stakes are very high,” Dr. Huang said. “Imagine if a similar scandal is reported again in China. It’s not just going to undermine the confidence of the company manufacturing the vaccine, it’s also going to hurt the reputation of AstraZeneca itself and their vaccine, too.”</div></div><div class="col-lg-6"><div class="article-paragraph">「風險非常高，」黃嚴忠說。「想像一下，如果中國再有類似醜聞被報導會怎樣。這不僅會損害對生產疫苗的公司的信心，也會損害阿斯利康及其疫苗的聲譽。」</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph"><b>‘The King of Vaccines’</b></div></div><div class="col-lg-6"><div class="article-paragraph"><b>「疫苗之王」</b></div></div></div><figure class="article-inline-photo large"><div class="img-box"><img src="../../../../../../static01.nyt.com/images/2020/10/05/business/00china-vaccine-1/00china-vaccine-1-master1050.html" alt="缺乏透明度及可疑的商業行為，已經動搖了公眾對中國製造疫苗的信心。" data-src="../../../../../../static01.nyt.com/images/2020/10/05/business/00china-vaccine-1/00china-vaccine-1-master1050.html"></div><figcaption><span>缺乏透明度及可疑的商業行為，已經動搖了公眾對中國製造疫苗的信心。</span> <cite>Imaginechina, via Associated Press</cite></figcaption></figure><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">As the chief executive of a small vaccine maker in the early 2000s, Mr. Du was looking to grow. He set his sights abroad, visiting pharmaceutical companies and biotechnology research institutes in Western countries, including the United States, Britain and France.</div></div><div class="col-lg-6"><div class="article-paragraph">本世紀初，在擔任一家小型疫苗製造商的首席執行官時，杜偉民就在尋找增長點。他把目光投向了國外，參觀了美、英、法等西方國家的製藥公司和生物技術研究機構。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">Mr. Du, then in his mid-30s, came away from his meetings with an urgent conclusion, he recalled in interviews with Chinese news outlets. It was a mistake for China to continue relying on foreign vaccines, Mr. Du had determined. They were expensive. And he worried that China’s dependence on other countries posed “hidden dangers to national security.”</div></div><div class="col-lg-6"><div class="article-paragraph">在接受中國媒體採訪時，杜偉民回憶說，當時35歲左右的他在結束這些會面後就得出了一個緊迫的結論。杜偉民認為，中國繼續依賴外國疫苗是個錯誤。那些疫苗太貴了。他也擔心中國對其他國家的依賴會「對國家安全帶來很大隱患」。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">“Vaccines for the Chinese people must firmly be in the hands of the Chinese,” Mr. Du <a rel="noopener noreferrer" target="_blank" href="http://cpc.people.com.cn/n/2014/0408/c87228-24841556.html">told</a> a state-owned newspaper, the Jiangxi Daily, in 2014.</div></div><div class="col-lg-6"><div class="article-paragraph">「中國人的疫苗必須牢牢地掌握在中國人的手裡，」杜偉民在2014年接受國有報紙《江西日報》的採訪時<a rel="noopener noreferrer" target="_blank" href="http://cpc.people.com.cn/n/2014/0408/c87228-24841556.html">表示</a>。</div></div></div></div><div class="article-body-aside col-lg-3"></div></div><div class="big_ad" id="medium-rectangle-ad-3" data-target="{&quot;pos&quot;:&quot;mid4&quot;,&quot;adv&quot;:&quot;&quot;}"><small>廣告</small></div><div class="article-partial"><div class="article-body-item col-lg-5"><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">His timing was good. After years of relying on multinational companies for crucial medicine, the Chinese government wanted to cultivate a homegrown vaccine industry, for many of the same reasons.</div></div><div class="col-lg-6"><div class="article-paragraph">他趕上的時機非常好。多年來依靠跨國企業提供關鍵藥品的中國政府，出於許多相同的原因，希望培育本土疫苗產業。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">State-run companies had long dominated the business in China, going back to the Mao era. As demand increased, entrepreneurs like Mr. Du saw an opportunity to build companies that could <a href="https://www.nytimes.com/2020/03/11/business/economy/coronavirus-china-trump-drugs.html">compete on the global stage</a>.</div></div><div class="col-lg-6"><div class="article-paragraph">從毛時代開始，國有企業長期主導著中國的商業。隨著需求增長，杜偉民這樣的企業家就看到了建立具有<a href="#https://cn.nytimes.com/usa/20200312/dc-virus-drug/">全球競爭力</a>的企業的機會。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">Many embraced partnerships with overseas vaccine makers, a strategy that China followed in other areas like technology and auto manufacturing. The international companies gained access to the Chinese market, while the Chinese companies secured valuable knowledge about production techniques and technology.</div></div><div class="col-lg-6"><div class="article-paragraph">許多企業都願意與外國疫苗製造商合作，這一戰略也被中國在科技和汽車製造等其他領域採用。這些跨國企業獲得了進入中國市場的機會，而中國企業則獲得了有關生產工藝和技術的寶貴知識。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">Such deals would help catapult Mr. Du, the son of farmers from a poor mountainous area of Jiangxi Province, into the big leagues.</div></div><div class="col-lg-6"><div class="article-paragraph">這樣的交易，讓杜偉民這個來自江西省貧困山區農民家庭的兒子得以登上更大的舞台。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">After helping found Beijing Minhai Biotechnology in 2004, he teamed up with the French pharmaceutical giant Sanofi Pasteur on a rabies vaccine. At the time, the Chinese government was leading a concerted effort to limit the spread of the disease, which killed more than 2,600 people in China that year.</div></div><div class="col-lg-6"><div class="article-paragraph">2004年，他幫助成立了北京民海生物科技有限公司，之後與法國製藥巨頭賽諾菲巴斯德(Sanofi Pasteur)合作研製狂犬病疫苗。當時，中國政府正在號召齊心協力控制該疾病的蔓延，那一年，狂犬病在中國造成2600多人死亡。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">In 2008, Mr. Du moved to expand his business by investing in Kangtai. The company was founded in 1992 with help from the American drugmaker Merck. Together, they produced a hepatitis B vaccine, as part of a joint venture aimed at improving health standards in China.</div></div><div class="col-lg-6"><div class="article-paragraph">2008年，杜偉民投資康泰，擴大了自己的業務。這家公司於1992年在美國製藥商默克(Merck)的幫助下成立。作為旨在提高中國衛生標準的共同行動的一部分，他們聯合生產了一種乙肝疫苗。</div></div></div></div><div class="article-body-aside col-lg-3"></div></div><div class="big_ad" id="medium-rectangle-ad-4" data-target="{&quot;pos&quot;:&quot;mid5&quot;,&quot;adv&quot;:&quot;&quot;}"><small>廣告</small></div><div class="article-partial"><div class="article-body-item col-lg-5"><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">His dealmaking would create an industry giant. Local media called him “<a rel="noopener noreferrer" target="_blank" href="http://cpc.people.com.cn/n/2014/0408/c87228-24841556.html?from=timeline&amp;from=1087293010&amp;weiboauthoruid=">the warrior of the vaccine kingdom.”</a></div></div><div class="col-lg-6"><div class="article-paragraph">他的交易手段將創造出一個行業巨頭。當地媒體稱他是「<a rel="noopener noreferrer" target="_blank" href="http://cpc.people.com.cn/n/2014/0408/c87228-24841556.html?from=timeline&amp;from=1087293010&amp;weiboauthoruid=">疫苗王國的勇士</a>」。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">His net worth was an estimated $7.4 billion until May, when Mr. Du transferred $3.5 billion worth of shares in his company to his ex-wife, Yuan Liping, in what Chinese news outlets described as China’s most expensive divorce ever. Ms. Yuan, a Canadian citizen, is now one of Canada’s richest women.</div></div><div class="col-lg-6"><div class="article-paragraph">截至今年5月，他的凈資產估值達到74億美元，他也在此時將價值35億美元的公司股份轉給了前妻袁莉萍，中國媒體將此舉稱為中國有史以來最昂貴的離婚。袁莉萍是加拿大公民，如今已經成為加拿大最為富有的女性之一。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">“From starting his company to getting rich to getting divorced,” China Times, a mainland news site, wrote about the tycoon, “the mysteries that he holds can only be solved with time.”</div></div><div class="col-lg-6"><div class="article-paragraph">「從發家、暴富到離婚，」大陸新聞網站華夏時報網在關於這位大亨的報導中寫道，「他身上的謎，只能交給時間來解答。」</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph"><b>Corporate Hardball</b></div></div><div class="col-lg-6"><div class="article-paragraph"><b>資本鐵腕</b></div></div></div><figure class="article-inline-photo large"><div class="img-box"><img src="../../../../../../static01.nyt.com/images/2020/10/05/business/00china-vaccines-3/merlin_143674044_b137f7f5-3e14-485f-ab6c-fdf3a3d8972c-master1050.html" alt="調查記者杜濤欣在寫了一篇批評杜偉民和中國藥品監管部門的文章後，被判誹謗罪。他已經離開了新聞界。「疫苗好像一件不可碰的事情，」他說。" data-src="../../../../../../static01.nyt.com/images/2020/10/05/business/00china-vaccines-3/merlin_143674044_b137f7f5-3e14-485f-ab6c-fdf3a3d8972c-master1050.html"></div><figcaption><span>調查記者杜濤欣在寫了一篇批評杜偉民和中國藥品監管部門的文章後，被判誹謗罪。他已經離開了新聞界。「疫苗好像一件不可碰的事情，」他說。</span> <cite>Giulia Marchi</cite></figcaption></figure><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">The timing seemed suspicious.</div></div><div class="col-lg-6"><div class="article-paragraph">時機看上去有些可疑。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">In 2010, the state-run China Youth Daily newspaper <a rel="noopener noreferrer" target="_blank" href="http://zqb.cyol.com/content/2010-04/05/content_3167311.htm">reported</a> that regulators had delayed telling the public that about 180,000 doses of a rabies vaccine were ineffective.<strong> </strong>The vaccine was made by Jiangsu Yanshen, then owned by Mr. Du of Kangtai.</div></div><div class="col-lg-6"><div class="article-paragraph">2010年，國營報紙《中國青年報》<a rel="noopener noreferrer" target="_blank" href="http://zqb.cyol.com/content/2010-04/05/content_3167311.htm">報導</a>稱，監管機構沒有及時將約有18萬劑狂犬病疫苗無效的信息告知公眾。這些疫苗由江蘇延申生產，該公司當時為康泰生物的杜偉民所有。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">During the delay, which lasted nine months, Mr. Du sold a roughly 51 percent stake in the company to the Simcere Pharmaceutical Group, another drug manufacturer, according to the Economic Observer website, a financial news outlet.</div></div><div class="col-lg-6"><div class="article-paragraph">據財經新聞媒體《經濟觀察報》網站報導，在長達9個月的拖延中，杜偉民將這家公司約51%的股份賣給了另一家製藥商先聲藥業集團。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">An investigative journalist, Du Taoxin, started digging. Industry insiders, he said, confirmed the reports, telling him that regulators held off on<strong> </strong>the announcement so that Du Weimin could sell the shares and not be held liable for the scandal.</div></div><div class="col-lg-6"><div class="article-paragraph">調查記者杜濤欣開始挖掘內幕。他表示，業內人士證實了這些報導，並告訴他，監管機構推遲發布公告，是為了讓杜偉民出售股份，從而不用為醜聞承擔責任。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">It lined up with a <a rel="noopener noreferrer" target="_blank" href="http://finance.cnr.cn/txcj/201409/t20140918_516458658.shtml">report</a> in the state-backed China National Radio. The article similarly named Mr. Du and found that the authorities had withheld the information so that<strong> </strong>Simcere would have to bear the reputational costs of the scandal.</div></div><div class="col-lg-6"><div class="article-paragraph">這與有政府背景的中國中央人民廣播電台的<a rel="noopener noreferrer" target="_blank" href="http://finance.cnr.cn/txcj/201409/t20140918_516458658.shtml">報導</a>一致。該篇文章同樣提到了杜偉民的名字，並發現當局隱瞞了這一信息，以使先聲藥業不得不承擔醜聞帶來的名譽損失。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">After reports of the faulty vaccines, Simcere issued a statement saying that the quality issues occurred before it invested in Jiangsu Yanshen, emphasizing that it bore “no responsibility for the incident.” Mr. Du, the pharmaceutical executive, would not comment.</div></div><div class="col-lg-6"><div class="article-paragraph">在疫苗問題被曝光後，先聲藥業發布聲明稱，疫苗質量問題發生在其成為江蘇延申的股東之前，強調稱自己與「本次事件沒有任何責任關聯」。作為江蘇延申的高管，杜偉民沒有置評。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">In August 2014, the journalist published his article under the headline “China’s Drug Regulators Caught Up in ‘Whistleblowing Scandals,’ Unveiling the Truth Behind Vaccine Cases.”</div></div><div class="col-lg-6"><div class="article-paragraph">2014年8月，這位記者以《食藥監總局官員身陷「舉報門」疫苗案大起底》為標題發表了文章。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">Many of the industry’s problems are born out of a symbiotic relationship with the government. China’s vaccines are administered through local communicable disease control centers.<strong> </strong>Those centers take a cut of the profit for certain types of vaccines, creating an incentive for <a href="https://www.nytimes.com/2016/11/02/business/international/china-rules-glaxo-bribes-sex-tape-whistleblower-cautionary-tale.html">corruption</a>.</div></div><div class="col-lg-6"><div class="article-paragraph">該行業的許多問題都是與政府的共生關係導致的。中國的疫苗由地方傳染病控制中心進行管理。這些中心要從某些類型疫苗的利潤分一杯羹，為<a href="https://www.nytimes.com/2016/11/02/business/international/china-rules-glaxo-bribes-sex-tape-whistleblower-cautionary-tale.html">腐敗</a>創造了誘因。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">From 2018 to 2020, there were 59 corruption lawsuits involving vaccine companies, according to an analysis by The New York Times. Fifty-four of them involved bribing local officials.</div></div><div class="col-lg-6"><div class="article-paragraph">根據《紐約時報》的一項分析，從2018年到2020年，共有59起涉及疫苗企業的腐敗訴訟。其中54起涉及賄賂地方官員。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">Kangtai sued the journalist, Du Taoxin, and his newspaper, Democracy and the Rule of Law, claiming defamation.</div></div><div class="col-lg-6"><div class="article-paragraph">康泰對記者杜濤欣及其工作的報社《民主與法制時報》提起訴訟，稱其誹謗。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">The journalist and his newspaper tried to defend the work, submitting what they viewed as other evidence of media pressure.</div></div><div class="col-lg-6"><div class="article-paragraph">杜濤欣及報社試圖為自己的作品辯護，提交了在他們看來是媒體壓力的其他證據。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">Guangdong Satellite, a state-backed television station, had apologized in September 2014 for “hurting the feelings” of Mr. Du Weimin after a prominent Chinese economist criticized the tycoon’s company in a program. The station retracted its story.</div></div><div class="col-lg-6"><div class="article-paragraph">2014年9月，官方電視台廣東衛視的一個節目中，一名著名中國經濟學家批評了這位大亨的企業。電視台隨後就節目造成的「精神損害」向杜偉民道歉，並撤回了報導。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">The 21st Century Business Herald, an influential business newspaper, had deleted seven articles that it published relating to Mr. Du’s company and the deaths of newborns who were given Kangtai’s hepatitis B vaccines in 2013, according to court documents. They had closely covered several of the deaths and reported that Mr. Du’s family had previously immigrated to Canada.</div></div><div class="col-lg-6"><div class="article-paragraph">法庭文件顯示，具有影響力的商業報紙《21世紀經濟報導》刪除了其發表過的七篇文章，這些文章均與杜偉民的公司及2013年接種康泰乙肝疫苗新生兒死亡有關。該報密切報導了幾起死亡事件，並且報導稱杜偉民一家此前已移民加拿大。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">As part of his defense, the journalist noted the article by China National Radio on the same topic. It’s unclear why those media outlets didn’t face legal action.</div></div><div class="col-lg-6"><div class="article-paragraph">作為其辯護的一部分，記者指出中國人民廣播電台也對同一題材進行過報導。尚不清楚為何這些媒體沒有面臨法律行動。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">The vaccine tycoon was represented by Zhang He. Mr. Zhang had also served as the lawyer for Yin Hongzhang, the drug regulator who was convicted of accepting bribes from Mr. Du.</div></div><div class="col-lg-6"><div class="article-paragraph">這位疫苗大亨的律師是張合，他還為國家食藥監局領導尹紅章辯護過，後者因為收受杜偉民賄賂被定罪。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">The journalist pointed to the bribery case as proof he had not defamed the executive in his article. Du Weimin acknowledged, in court documents, that he was the Mr. Du who had bribed Mr. Yin.</div></div><div class="col-lg-6"><div class="article-paragraph">杜濤欣認為，這起受賄案可以證明，他的文章沒有對這位高管進行誹謗。在法庭文件中，杜偉民承認他正是曾向尹紅章行賄的「杜某」。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">But the judge said that information was not pertinent to the case. The judge, in forming his ruling, also cited the journalist’s refusal to disclose the identities of his anonymous sources.</div></div><div class="col-lg-6"><div class="article-paragraph">但法官表示，這一信息與該案無關。在進行裁決時，該法官還將該名記者拒絕披露其匿名信源的身份作為根據。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">On November 2016, Du Taoxin was convicted of “hurting the reputation” of Du Weimin. The court said Mr. Du’s articles had “led to a decline in the society’s evaluation of Du Weimin and infringed on his reputation.”</div></div><div class="col-lg-6"><div class="article-paragraph">2016年11月，杜濤欣被判「侵害」杜偉民「名譽權」。法院表示杜濤欣的文章「導致杜偉民的社會評價降低，侵害了其名譽權」。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">He had to pay Mr. Du $300, and his newspaper had to delete the article.</div></div><div class="col-lg-6"><div class="article-paragraph">他必須要賠償杜偉民2000元人民幣，報社必須刪除報導。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">The sentence was meted out on Chinese Journalists’ Day. Mr. Du quit journalism a year later.</div></div><div class="col-lg-6"><div class="article-paragraph">這一判決是在中國記者節當天發出的。一年後，杜濤欣辭職不做記者了。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">“Vaccines seem to be an untouchable issue,” said Mr. Du. “No matter how I persisted in chasing the truth, it always seemed elusive. I had all the evidence, but I knew that this was a lawsuit that could never be won.”</div></div><div class="col-lg-6"><div class="article-paragraph">「疫苗好像一件不可碰的事情，」杜濤欣說。「無論我怎麼堅持追逐地真相，真相好像是不可能的事情。我拿出所有的證據，但我知道這是一場不可能打贏的官司。」</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph"><b>Preferential Treatment</b></div></div><div class="col-lg-6"><div class="article-paragraph"><b>優待</b><br></div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">A group of Chinese families have led a <a href="https://www.nytimes.com/2018/07/30/world/asia/china-protest-faulty-vaccines.html">small but spirited effort</a> in recent years to regulate the nation’s vaccine industry more strictly. The government, which views <a href="https://www.nytimes.com/2015/07/23/world/asia/china-crackdown-human-rights-lawyers.html">political organizing</a> as a threat to the Communist Party, has sought to silence their campaign.</div></div><div class="col-lg-6"><div class="article-paragraph">近年來，一批中國家庭牽頭髮起了一項<a href="#https://cn.nytimes.com/china/20180731/china-protest-faulty-vaccines/">規模不大但堅定的行動</a>，試圖讓這個國家的疫苗行業得到更嚴格監管。將<a href="https://www.nytimes.com/2015/07/23/world/asia/china-crackdown-human-rights-lawyers.html">政治組織</a>視為對共產黨威脅的政府已經在尋求讓他們的活動噤聲。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">Officials have harassed and detained mothers, fathers and grandmothers, charging them with “disrupting public order” or “picking quarrels and provoking trouble.” In October, the authorities in the central province of Henan detained He Fangmei, one of the most outspoken critics of Chinese vaccine companies in China, according to her friends, who spoke on the condition of anonymity given the legal sensitivity.</div></div><div class="col-lg-6"><div class="article-paragraph">官員已經騷擾、拘留了孩子們的母親、父親和祖母，指控他們「擾亂公共秩序」或「尋釁滋事」。據其朋友說，10月，河南省當局拘留了何方美。她是中國最直言不諱批評中國疫苗公司的人之一。鑒於法律敏感性，她的朋友要求匿名。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">Lawyers representing vaccine activists have faced severe punishments. Many of the online groups families use to share grievances and coordinate protests on the Chinese social messaging app WeChat have been shut down.</div></div><div class="col-lg-6"><div class="article-paragraph">為疫苗活動人士代理案件的律師面臨嚴重處罰。許多家庭用來傾訴不滿和協調抗議的微信群被關停。</div></div></div><figure class="article-inline-photo large"><div class="img-box"><img src="../../../../../../static01.nyt.com/images/2020/10/05/business/00china-vaccine-2/00china-vaccine-2-master1050.html" alt="深圳康泰生物製品公司生產的疫苗供應量約佔全球的四分之一。" data-src="../../../../../../static01.nyt.com/images/2020/10/05/business/00china-vaccine-2/00china-vaccine-2-master1050.html"></div><figcaption><span>深圳康泰生物製品公司生產的疫苗供應量約佔全球的四分之一。</span> <cite>Imaginechina, via Associated Press</cite></figcaption></figure><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">Liao Fangsheng tried to petition the central government after his son, Pengyong, was found to have viral encephalitis. Mr. Liao said his son was a happy and healthy 18-month-old before he took a vaccine made by Kangtai.</div></div><div class="col-lg-6"><div class="article-paragraph">在兒子彭勇（音）被發現患有病毒性腦炎後，廖方生（音）試圖向中央政府請願。廖方生說，在兒子接種康泰生產的疫苗前，他是一個快樂健康的一歲半寶寶。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">Two or three days after the inoculation, Pengyong developed a low-grade fever and then fell into a coma for 17 days. In December 2019, the local health commission said it was a “coincidence” that the boy had become ill after taking the vaccine.</div></div><div class="col-lg-6"><div class="article-paragraph">在接種兩到三天後，彭勇出現低燒，隨後陷入昏迷長達17天。2019年12月，當地衛健委表示這名男孩接種疫苗後生病是個「巧合」。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">Mr. Liao didn’t have any scientific evidence, but he remained convinced that the vaccine was connected. He traveled to Beijing to the National Health Commission and the petition bureau, where people go to seek help for their grievances. They directed him to other government departments, what he described as “buck-passing.”</div></div><div class="col-lg-6"><div class="article-paragraph">廖方生沒有科學方面的證據，但他仍然相信此事與疫苗有關。他前往北京的國家衛健委和信訪局。他們把他推給了其他政府部門，廖認為這是「推諉扯皮」。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">After he tried to seek help outside the Chinese Communist Party’s leadership compound, he was detained for a week in his hometown in southeastern Jiangxi Province. The authorities said he was “disrupting the order of a workplace,” according to a copy of the detention notice.</div></div><div class="col-lg-6"><div class="article-paragraph">他試圖在中國共產黨領導人大院外尋求幫助，結果被送回自己的家鄉江西省拘留一週。一份拘留通知書顯示，當局說他「擾亂單位秩序」。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">“They all wear one pair of trousers, their superiors protect their subordinates,” said Mr. Liao. “No one looks at any of the materials I hand over. There is no space for me to talk. Where do you think the law is? Where is the government?”</div></div><div class="col-lg-6"><div class="article-paragraph">「他們都是穿一條褲子，上級保護下級，」廖方生說。「交的才材料沒人看。我說話的地方都沒有。你說這個法律在哪裡？政府在哪裡？」</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">The Chinese government may have reason to shield the industry from criticism. In a country of 1.4 billion people, rumors can quickly spread, undermining China’s effort to protect the health of the nation. But the dearth of information and lack of legal recourse can also breed a deep distrust.</div></div><div class="col-lg-6"><div class="article-paragraph">中國政府保護這個行業不受批評可能是有原因的。在一個有著14億人口的國家，謠言傳播得很快。但信息匱乏和法律資源的缺失也可能會滋生深深的不信任感。<br></div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">In 2010, dozens of elementary school students from southern Guangdong Province experienced headaches, vomiting and limb weakness after they were injected with Kangtai’s hepatitis B vaccine.</div></div><div class="col-lg-6"><div class="article-paragraph">2010年，中國南部廣東省有數十名小學生在注射康泰的乙肝疫苗後出現頭疼、嘔吐和四肢無力問題。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">A provincial health official attributed the problems to a “mass-based psychogenic reaction,” according to the state-run China News Service.</div></div><div class="col-lg-6"><div class="article-paragraph">據官方新聞機構新華社報導，一名省衛生官員將問題歸咎於「群體性心因性反應」。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">The official, Peng Guowen, director of the institute of immunization of the Guangdong Provincial Center for Disease Control and Prevention, said that most of the symptoms such as dizziness or abdominal pain were “subjective” and that none of the students developed fever. He blamed rumors that had spread among the news media and society about the safety of vaccines, saying they had “aggravated” the students’ anxiety and caused the vomiting.</div></div><div class="col-lg-6"><div class="article-paragraph">這位名叫彭國文的官員是廣東省疾控中心計劃免疫所所長，他說像頭暈或腹痛這樣的癥狀大多是「主觀的」，並且這些學生都沒有出現發燒。他指責媒體和社會上散布的有關疫苗安全性的謠言，稱這「加劇」了學生的緊張情緒，從而導致嘔吐。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">In a separate news conference,<strong> </strong>a reporter asked how the government could conclude that the students’ adverse reactions had nothing to do with the vaccine before the test results were out. Officials did not answer, according to The Southern Metropolis Daily.</div></div><div class="col-lg-6"><div class="article-paragraph">在另一場新聞發布會上，一名記者問政府如何在沒有得到檢測結果的情況下就判斷不良反應與疫苗無關。據《南方都市報》報導，官員們沒有回答。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">In 2013, after reports emerged that 17 infants had died after they took the same vaccine, the Chinese media and the public called Mr. Du a “baby-killer.” The government stopped the sale of the vaccines in December for over a month.</div></div><div class="col-lg-6"><div class="article-paragraph">2013年，有報導稱17名嬰兒在接種了同一種疫苗後死亡，杜偉民被中國媒體和民眾稱為「殺嬰者」。政府在12月叫停了疫苗的銷售，時間持續逾一個月。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">It lifted the suspension after it concluded that the company was not to blame. The release about the official investigation provided little detail. It mainly took note of the deaths and listed their causes, which included pneumonia, heart disease and diarrhea, according to a government statement.</div></div><div class="col-lg-6"><div class="article-paragraph">在認定責任不在該公司後，政府取消了禁令。官方公布的調查結果沒有透露多少細節。據一份政府聲明稱，報告主要是表示了解到死亡事件的發生，並列出死因，包括肺炎、心臟病和腹瀉。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">China has been less forthcoming about questions of vaccine safety than other countries. In the United States, the federal government often commissions in-depth assessments after manufacturers report problems with vaccines. In South Korea, where a string of deaths recently undermined confidence in a flu vaccine, the government <a href="https://www.nytimes.com/2020/11/24/world/asia/korea-flu-vaccine-coronavirus-scare.html">released detailed data</a> on the deaths as it worked to restore public trust.</div></div><div class="col-lg-6"><div class="article-paragraph">相比其他國家，中國一直在疫苗安全性的問題上不太透明。在美國，聯邦政府在生產商報告疫苗問題後通常會委託進行深度評估。在韓國，近期有一系列死亡事件導致一種流感疫苗遭遇信任危機，政府隨即就死亡案例公布了<a href="https://www.nytimes.com/2020/11/24/world/asia/korea-flu-vaccine-coronavirus-scare.html">詳細的數據</a>，以恢復公眾的信心。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">As China now tries to burnish its global standing as a scientific and medical power, the reputation of its vaccine makers is all the more important.</div></div><div class="col-lg-6"><div class="article-paragraph">如今中國正在努力建立科學和醫學大國的國際聲譽，疫苗生產商的聲譽問題變得空前重要。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">For decades, the industry has focused on selling products in China, believing that the domestic market was big enough to sustain the business. Few companies have discovered products with worldwide impact.</div></div><div class="col-lg-6"><div class="article-paragraph">幾十年來，這個產業一直側重於在國內銷售產品，認為國內市場的規模足以維持運轉。很少有公司開發出能產生國際影響的產品。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">Only five Chinese vaccines have been preapproved for export by the World Health Organization. By contrast, India has 47 vaccines that have passed those requirements.</div></div><div class="col-lg-6"><div class="article-paragraph">只有五種中國疫苗得到了世衛組織的出口預審批。相比之下，印度有47種疫苗達到了這一要求。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">To China, the <a href="https://www.nytimes.com/2020/11/17/business/china-coronavirus-vaccine-safety.html">pandemic</a> offers a chance to transform the industry into a global player — and it’s investing heavily in champions like Kangtai.</div></div><div class="col-lg-6"><div class="article-paragraph">在中國，<a href="https://www.nytimes.com/2020/11/17/business/china-coronavirus-vaccine-safety.html">新冠疫情</a>給這個產業帶來了走向世界的機遇——它正在向康泰這樣的領先企業注入巨資。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">The local government in the southern city of Shenzhen gave the company a 20,000-square-meter piece of land, which is now the base for Kangtai’s coronavirus vaccine plant. Kangtai has also received government funding as part of the country’s effort to fight the pandemic.</div></div><div class="col-lg-6"><div class="article-paragraph">南方城市深圳的地方政府給了康泰一塊20000平方米的地，用於建造公司的新冠疫苗工廠。康泰還得到了中國為防疫工作撥發的經費。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">AstraZeneca and the University of Oxford announced late last month that their vaccine <a href="https://www.nytimes.com/2020/11/23/business/astrazeneca-oxford-coronavirus-vaccine.html">appeared effective</a>, although the level of effectiveness is disputed. Under the deal with AstraZeneca, Kangtai will produce 200 million doses for mainland China.</div></div><div class="col-lg-6"><div class="article-paragraph">阿斯利康和牛津大學上月底宣布，他們的疫苗看起來是有效的，儘管有效水平存在爭議。根據與阿斯利康的協議，康泰將為中國大陸生產2億劑疫苗。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">In late September, Kangtai announced that it would start testing its own coronavirus vaccine on people in China after results showed that it protected mice and monkeys.</div></div><div class="col-lg-6"><div class="article-paragraph">9月底，康泰宣布在中國開展自己研發的新冠疫苗的測試，此前該疫苗經實驗證明對鼠、猴能起到保護作用。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">In an interview with China Central Television, the state broadcaster, Zheng Haifa, a top scientist at Kangtai, said the company was working to achieve a breakthrough in developing a vaccine “as soon as possible” to meet the demands of China’s top leader, Xi Jinping, who has called on the nation’s pharmaceutical companies to lead an <a href="https://www.nytimes.com/2020/09/11/business/china-vaccine-diplomacy.html" title="Link: https://www.nytimes.com/2020/09/11/business/china-vaccine-diplomacy.html">all-out effort</a> to produce a vaccine.</div></div><div class="col-lg-6"><div class="article-paragraph">在接受官方媒體中央電視台採訪時，康泰首席科學家鄭海發表示，公司正力爭「儘快」在疫苗研發上實現突破，以完成國家最高領導人習近平交予的任務，後者曾呼籲全國藥企開展疫苗生產的全面行動。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">Mr. Zheng said the company’s mission was simple: “to provide safe and effective protection for the lives and health of people.”</div></div><div class="col-lg-6"><div class="article-paragraph">鄭海發說，公司的使命很簡單：「為人民生命健康安全提供有效保障。」</div></div></div></div><div class="article-body-aside col-lg-3"></div></div></section></div><div class="col-lg-12 row author-info-container"><footer class="author-info"><p>Katie Thomas對本文有報導貢獻。Elsie Chen、Amber Wang、Liu Yi、Albee Zhang對本文有研究貢獻。</p><p>黃瑞黎(Sui-Lee Wee)是《紐約時報》駐北京分社記者。她報導中國近十年，關注社會議題、性別、基因監測、醫療保健以及人口和經濟的交叉議題。歡迎在Twitter上關注她 <a rel="nofollow" target="_blank" href="https://twitter.com/suilee">@suilee</a>。</p><p>赫海威(Javier C. Hernández)是《紐約時報》負責報導中國的記者。他報導了習近平領導下專制國家的崛起、#MeToo運動等社會理念的發展以及農民工和污染受害者等中國最弱勢公民的困境。歡迎在Twitter上關注他<a rel="nofollow" target="_blank" href="https://twitter.com/HernandezJavier"> @HernandezJavier</a>。</p><p>翻譯：紐約時報中文網</p><p><a rel="nofollow" target="_blank" href="https://www.nytimes.com/2020/12/07/business/china-vaccine-astrazeneca.html">點擊查看本文英文版。</a></p></footer></div></article><div class="container article-footer"><div class="row"><div class="col-lg-12 dual-refer-cont"><div class="related-cont"><h4>相關報導</h4><ul class="refer-list"><li class="article-refer"><div class="refer-list-item"><a href="../../../../20200928/china-coronavirus-vaccine/zh-hant/index.html" title="中國豪賭新冠疫苗，數萬人已接種"><div><h3 class="refer-list-headline">中國豪賭新冠疫苗，數萬人已接種</h3><p class="refer-pubdate">2020年9月28日</p></div><img alt="中國豪賭新冠疫苗，數萬人已接種" src="../../../../../../static01.nyt.com/images/2020/09/24/business/00china-vaccines-4/00china-vaccines-4-thumbLarge.html" width="75" height="75"></a></div></li><li class="article-refer"><div class="refer-list-item"><a href="#https://cn.nytimes.com/asia-pacific/20201125/korea-flu-vaccine-coronavirus-scare/zh-hant/" title="韓國流感疫苗恐慌給世界的寶貴一課"><div><h3 class="refer-list-headline">韓國流感疫苗恐慌給世界的寶貴一課</h3><p class="refer-pubdate">2020年11月25日</p></div><img alt="韓國流感疫苗恐慌給世界的寶貴一課" src="../../../../../../static01.nyt.com/images/2020/11/23/world/00skorea-vaccine01/00skorea-vaccine01-thumbLarge.html" width="75" height="75"></a></div></li><li class="article-refer"><div class="refer-list-item"><a href="#https://cn.nytimes.com/china/20181018/china-vaccine-fine/zh-hant/" title="中國對假疫苗製造商開巨額罰單"><div><h3 class="refer-list-headline">中國對假疫苗製造商開巨額罰單</h3><p class="refer-pubdate">2018年10月18日</p></div><img alt="中國對假疫苗製造商開巨額罰單" src="../../../../../../static01.nyt.com/images/2018/10/18/world/18Chinavaccine1/18Chinavaccine1-thumbLarge.html" width="75" height="75"></a></div></li><li class="article-refer"><div class="refer-list-item"><a href="#https://cn.nytimes.com/china/20180820/china-vaccines-scandal/zh-hant/" title="中國疫苗醜聞10名涉事官員遭免職"><div><h3 class="refer-list-headline">中國疫苗醜聞10名涉事官員遭免職</h3><p class="refer-pubdate">2018年8月20日</p></div><img alt="中國疫苗醜聞10名涉事官員遭免職" src="../../../../../../static01.nyt.com/images/2018/08/18/world/18china-vaccine/18china-vaccine-thumbLarge.html" width="75" height="75"></a></div></li><li class="article-refer"><div class="refer-list-item"><a href="#https://cn.nytimes.com/china/20160419/c19chinavaccine/zh-hant/" title="疫苗事件再次拷問中國政府公信力"><div><h3 class="refer-list-headline">疫苗事件再次拷問中國政府公信力</h3><p class="refer-pubdate">2016年4月19日</p></div><img alt="疫苗事件再次拷問中國政府公信力" src="../../../../../../static01.nyt.com/images/2016/04/15/world/xxCHINA-VACCINE-web1/xxCHINA-VACCINE-web1-thumbLarge.html" width="75" height="75"></a></div></li></ul></div></div><div class="col-lg-12"><div class="related hot_article"><h5 class="related-title">最受歡迎</h5><ol class="related-articles"><li><a href="#https://cn.nytimes.com/opinion/20220127/pakistan-united-states-china/zh-hant/?utm_source=top10-in-article&amp;utm_medium=articlepage&amp;utm_campaign=web"><article><h4>「巴鐵」軍方為什麼想與中國保持距離？</h4><img alt="「巴鐵」軍方為什麼想與中國保持距離？" src="../../../../../../static01.nyt.com/images/2022/01/24/opinion/21Rafiq1/21Rafiq1-thumbLarge.jpg"></article></a></li><li><a href="#https://cn.nytimes.com/usa/20220127/computer-chip-shortage-taiwan/zh-hant/?utm_source=top10-in-article&amp;utm_medium=articlepage&amp;utm_campaign=web"><article><h4>戰棋推演報告稱台灣半導體工廠停產可能引發中美衝突</h4><img alt="戰棋推演報告稱台灣半導體工廠停產可能引發中美衝突" src="../../../../../../static01.nyt.com/images/2022/01/26/us/politics/26dc-wargames/merlin_177315390_5fcf8532-e370-4f81-8f99-45c6c83044f4-thumbLarge.jpg"></article></a></li><li><a href="#https://cn.nytimes.com/opinion/20220126/china-covid-19/zh-hant/?utm_source=top10-in-article&amp;utm_medium=articlepage&amp;utm_campaign=web"><article><h4>中國追求「清零」將把國家置於災難之中</h4><img alt="中國追求「清零」將把國家置於災難之中" src="../../../../../../static01.nyt.com/images/2022/01/25/opinion/25emanuel/25emanuel-thumbLarge.jpg"></article></a></li><li><a href="#https://cn.nytimes.com/sports/20220127/peng-shuai-china-australian-open/zh-hant/?utm_source=top10-in-article&amp;utm_medium=articlepage&amp;utm_campaign=web"><article><h4>澳網再現「彭帥在哪裡」：球員和觀賽者拒絕遺忘、為其發聲</h4><img alt="澳網再現「彭帥在哪裡」：球員和觀賽者拒絕遺忘、為其發聲" src="../../../../../../static01.nyt.com/images/2022/01/26/sports/26aus-china1/merlin_199503951_9c695f25-2b8e-41b4-9c97-bf91de7aa190-thumbLarge.jpg"></article></a></li><li><a href="#https://cn.nytimes.com/usa/20220125/gang-chen-mit-china/zh-hant/?utm_source=top10-in-article&amp;utm_medium=articlepage&amp;utm_campaign=web"><article><h4>「我們在殘害我們自己」：華裔教授陳剛案背後的憤怒與幻滅</h4><img alt="「我們在殘害我們自己」：華裔教授陳剛案背後的憤怒與幻滅" src="../../../../../../static01.nyt.com/images/2022/01/24/science/24CHEN-promo/24CHEN-promo-thumbLarge.jpg"></article></a></li><li><a href="#https://cn.nytimes.com/opinion/20220127/virtual-reality-simulation/zh-hant/?utm_source=top10-in-article&amp;utm_medium=articlepage&amp;utm_campaign=web"><article><h4>你可以開始相信，我們有可能會活在虛擬現實裡</h4><img alt="你可以開始相信，我們有可能會活在虛擬現實裡" src="../../../../../../static01.nyt.com/images/2022/01/26/opinion/26manjoo-image/26manjoo-image-thumbLarge.jpg"></article></a></li><li><a href="#https://cn.nytimes.com/china/20220124/winter-olympics-china-beijing-xi-jinping/zh-hant/?utm_source=top10-in-article&amp;utm_medium=articlepage&amp;utm_campaign=web"><article><h4>不再取悅世界：一屆展現習近平全面願景的冬奧會</h4><img alt="不再取悅世界：一屆展現習近平全面願景的冬奧會" src="../../../../../../static01.nyt.com/images/2022/01/13/world/00xi-olympics-30/00xi-olympics-30-thumbLarge.jpg"></article></a></li><li><a href="../../../../20220126/imf-world-economic-report/zh-hant/indexf61c.html?utm_source=top10-in-article&amp;utm_medium=articlepage&amp;utm_campaign=web"><article><h4>國際貨幣基金組織稱中美經濟放緩將拖累全球經濟</h4><img alt="國際貨幣基金組織稱中美經濟放緩將拖累全球經濟" src="../../../../../../static01.nyt.com/images/2022/01/25/multimedia/25global-econ-brf/25global-econ-brf-thumbLarge-v2.jpg"></article></a></li><li><a href="#https://cn.nytimes.com/asia-pacific/20220126/north-korea-launches-missiles-kim/zh-hant/?utm_source=top10-in-article&amp;utm_medium=articlepage&amp;utm_campaign=web"><article><h4>朝鮮突然頻繁試射導彈傳遞了什麼信息？</h4><img alt="朝鮮突然頻繁試射導彈傳遞了什麼信息？" src="../../../../../../static01.nyt.com/images/2022/01/21/world/00nkorea-gameplan-01/00nkorea-gameplan-01-thumbLarge.html"></article></a></li><li><a href="#https://cn.nytimes.com/china/20220124/china-zero-covid-policy/zh-hant/?utm_source=top10-in-article&amp;utm_medium=articlepage&amp;utm_campaign=web"><article><h4>多地封鎖引發沮喪與抱怨，中國「清零」政策還能走多遠？</h4><img alt="多地封鎖引發沮喪與抱怨，中國「清零」政策還能走多遠？" src="../../../../../../static01.nyt.com/images/2022/01/20/world/00virus-china-lockdown-01/00virus-china-lockdown-01-thumbLarge.html"></article></a></li></ol></div></div></div></div></div><footer class="row copy-footer">&copy; 2022 The World Economy Observer.<ul class="footerLinkList"><li class="footerLink"><a rel="nofollow" href="/ad/">广告</a></li><li class="footerLink"><a rel="nofollow" href="/about-us/">关于我们</a></li><li class="footerLink"><a rel="nofollow" href="/contact/">联系我们</a></li><li class="footerLink"><a rel="nofollow" href="/tos/">服务条款</a></li><li class="purr-content"></li></ul></footer><script src="../../../../../../d1f1eryiqyjs0r.cloudfront.net/js/libs/require619b.js?v=f1810d8"></script><script src="../../../../../../d1f1eryiqyjs0r.cloudfront.net/js/web/article.min619b.js?v=f1810d8"></script></main></body>
<!-- Mirrored from cn.nytimes.com/business/20201207/china-vaccine-astrazeneca/zh-hant/dual/ by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 28 Jan 2022 14:11:36 GMT -->
</html>